Our goals

To benchmark various existing anto-OSE Abs

To select an optimal combination with native IL-2 or IL-2IT

Evaluate the pharmacokinetics and tissue distribution of IL-2IT

in mice and non-human primates

To evaluate IL-2IT candidates

for therapeutic efficacy in inflammatory cardiovascular diseases (iCVD)

To evaluate different modalities of IL-2IT use

repeated protein injections, single injection of a recombinant AAV encoding the IL-2IT or intervalled injections of mRNA coding for IL-2IT formulated into LNPs

To optimise a process

for production of the protein and to perform a toxicity study in mice